Diagnostic Accuracy of Artificial Intelligence in Predicting Anti-VEGF Treatment Response in Diabetic Macular Edema:...

Background/Objectives: Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the standard management. However, treatment response varies significantly among patients, necessitating predictive tools. This systematic review and meta-analysis evaluated the diagnostic accuracy of artificial intelligence (AI) models in predicting anti-VEGF treatment response in DME patients. Methods: We conducted a dedicated literature review following PRISMA 2020 guidelines, searching PubMed, Web of Science, Embase, Scopus, and Cochrane Library databases from inception up to 30 September 2025. Studies evaluating AI-based prediction models for anti-VEGF response in DME patients were included. The primary outcomes were sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). A bivariate random-effects meta-analysis was performed using available diagnostic accuracy data. Results: From 3107 participants across 18 studies, six studies with 427 participants provided complete diagnostic accuracy data for meta-analysis. The pooled sensitivity was 86.4% (95% CI: 82.1-90.1%) and the specificity was 77.6% (95% CI: 72.8-82.0%). The summary AUC was 0.89 with a diagnostic odds ratio of 22.0 (95% CI: 12.8-37.9). AI models demonstrated superior performance compared to other methods in 87.5% of comparative studies. Moderate heterogeneity was observed (I² = 45.2%). Conclusions: AI models demonstrate good diagnostic accuracy for predicting anti-VEGF treatment response in DME patients, with a promising role for improving personalized management strategies and improved outcomes.